AI Science Tracker
EN

Discovery of novel selective PI3Kγ inhibitors through combining machine learning-based virtual screening with multiple protein structures and bio-evaluation

School of Pharmaceutical Sciences, Jiangnan University, Wuxi, Jiangsu 214122, China · 20 Apr 2021 · medicine

Discovery

Discovery of novel selective PI3Kγ inhibitors through combining machine learning-based virtual screening with multiple protein structures and bio-evaluation

Source check: Source checked. Not independent scientific confirmation.

Finding: Multi-structure machine-learning virtual screening selected PI3Kγ inhibitor JN-KI3 from a large chemical library. Enzymatic assays found selective PI3Kγ inhibition and cancer-cell assays reported selective cytotoxicity in hematologic cell lines; these experiments support an in-study discovery, not clinical efficacy.

Technology: Machine-learning virtual screening across multiple protein structures prioritized PI3Kγ inhibitor JN-KI3.

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
Machine-learning virtual screening across multiple protein structures prioritized PI3Kγ inhibitor JN-KI3.
Test and result
Virtual screening identified JN-KI3; cell-free enzyme assays reported selective PI3Kγ inhibition and cell assays reported selective cytotoxicity in hematologic cancer lines.
Limitation / still unknown
These assays were conducted within the discovery study; in-vivo therapeutic benefit and clinical efficacy were not established.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://europepmc.org/article/MED/35127160 · https://pmc.ncbi.nlm.nih.gov/articles/PMC8800018/ · https://pubmed.ncbi.nlm.nih.gov/35127160/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.